Risks Associated With Lentiviral Vector Exposures and Prevention Strategies
Document Type
Article
Publication Date
12-2016
Abstract
Lentiviral vectors (LVVs) are powerful genetic tools that are being used with greater frequency in biomedical laboratories and clinical trials. Adverse events reported from initial clinical studies provide a basis for risk assessment of occupational exposures, yet many questions remain about the potential harm that LVVs may cause. We review those risks and provide a framework for principal investigators, Institutional Biosafety Committees, and occupational health professionals to assess and communicate the risks of exposure to staff. We also provide recommendations to federal research and regulatory agencies for tracking LVV exposures to evaluate long-term outcomes. U.S. Food and Drug Administration approved antiviral drugs for HIV have theoretical benefits in LVV exposures, although evidence to support their use is currently limited. If treatment is appropriate, we recommend a 7-day treatment with an integrase inhibitor with or without a reverse transcriptase inhibitor within 72 hours of exposure.
Repository Citation
Schlimgen, R.,
Howard, J.,
Wooley, D. P.,
Thompson, M.,
Baden, L.,
Yang, O.,
Christiani, D.,
Mostoslavsky, G.,
Diamond, D.,
Gilman, E.,
Byers, K.,
Winters, T.,
Gelfand, J. A.,
Fujimoto, G.,
Hudson, T. W.,
& Vyas, J. M.
(2016). Risks Associated With Lentiviral Vector Exposures and Prevention Strategies. Journal of Occupational and Environmental Medicine, 58 (12), 1159-1166.
https://corescholar.libraries.wright.edu/ncbp/1131
DOI
10.1097/JOM.0000000000000879
